NL-OMON30396招募中不适用
ong-term follow-up of patients with extrahepatic biliary atresie and Kasai hepatoportoenterostomy: assessment of abnormalities on MR imaging and implications for follow-up. - MR imaging after Kasai portoenterostomy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •. patients that underwent Kasai portoenterostmy > 10 years ago for
- •extrahepatic biliary atresia
- •. patients did not undergo livertransplantation
- •. signed informed consent
排除标准
- •- severe cardiovascular or pulmonary condition
- •- pregnancy or lactation
- •- cardiac pacemaker, or presence of any other metal objects within the body
- •- metal workers
- •- severe claustrophobic complaints
研究者
相似试验
尚未招募
不适用
ONG-TERM FOLLOW-UP OF HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH INTERFERON ALFA: RELATION TO POLYMORPHISMS IN IL28B AND APOLIPOPROTEIN E LOCI (INTERFERLONG STUDY)liver inflammation1001965410047438chronic hepatitis BNL-OMON39063Academisch Medisch Centrum135
已完成
不适用
ong-term clinical outcome of chronic hepatitis B naive patients treated with entecavir and tenofovir in KoreaCertain infectious and parasitic diseasesKCT0008111Hallym University Medical Center-Dongtan2,000
撤回
2 期
Follow Up of Patients Chronic Hepatitis B (CHB) Treated With Sebivo Using the 13C Methacetin Breath TestChronic Hepatitis BNCT01204827Hadassah Medical Organization
进行中（未招募）
1 期
Study to evaluate long term effect of an experimental approach of gene therapy to treat ß-thalassemia major, know also as transfusion dependent ß-thalassemia, and the sickle cell disease.Subjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-ITBLUEBIRD BIO, INC.94
进行中（未招募）
1 期
ASubjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-GBbluebird bio, Inc.94